Measurable residual disease-driven treatment in first-line chronic lymphocytic leukaemia.

Autor: Davids MS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Lin KH; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Mohamed AI; Department of Haematology, Mid Yorkshire Teaching Hospitals NHS Trust, Wakefield, UK., Munir T; Department of Haematology, St James's University Hospital, Leeds, UK., Eyre TA; Department of Haematology, Churchill Hospital, Oxford, UK.
Jazyk: angličtina
Zdroj: British journal of haematology [Br J Haematol] 2024 Nov 13. Date of Electronic Publication: 2024 Nov 13.
DOI: 10.1111/bjh.19902
Abstrakt: The therapeutic paradigm for patients suffering from chronic lymphocytic leukaemia continues to rapidly evolve. Fixed duration therapies continue to develop using novel-novel non-chemotherapeutic combinations. B-cell lymphoma 2 (BCL2) inhibitors in combination with either anti-CD20 antibody or Bruton tyrosine kinase inhibitors are able to achieve deep responses. Levels of attained 'negative' measurable residual disease (MRD, also known as minimal residual disease) have been shown to predict survival outcomes in a number of settings, including following immunochemotherapy and BCL2-combinations. This review will outline the current data supporting fixed duration treatment approaches, the use of MRD in clinical practice, alongside the challenges and possibilities for MRD utility in the future.
(© 2024 British Society for Haematology and John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz: